Rtw Investments Adds $20M in Dianthus Therapeutics, Inc. ($DNTH)

RTW Investments has taken a new position in Dianthus Therapeutics, Inc. (NasdaqCM: DNTH). According to its latest 13F filing with the SEC, RTW acquired 248,063 shares, valued at approximately $20.36 million. This move marks a significant entry into the biotechnology company.

What Changed in RTW Investments' Dianthus Therapeutics Position

RTW Investments' new stake in Dianthus Therapeutics amounts to 248,063 shares, with a total value of about $20.36 million. This acquisition establishes a fresh position, as the fund previously held no shares in the company.

Other Institutional Activity in Dianthus Therapeutics

Several other institutional investors have also adjusted their positions in Dianthus Therapeutics. FMR LLC increased its stake by 1,336,357 shares, reaching a total of 7,767,686 shares worth roughly $651.86 million. BlackRock, Inc. added 1,260,467 shares, bringing its total to 3,175,703 shares valued at about $266.50 million. RA Capital Management, L.P. grew its holdings by 1,000,000 shares, ending with 2,611,733 shares worth approximately $219.18 million. Wellington Management Group LLP slightly increased its position by 92,593 shares, resulting in 2,595,783 shares valued at $217.84 million. Fairmount Funds Management LLC added 400,000 shares, totaling 2,537,191 shares worth $212.92 million.

Dianthus Therapeutics Stock Snapshot

Shares of Dianthus Therapeutics, trading under the ticker DNTH on NasdaqCM, are priced around $82.07. The company has a market cap of roughly $4.49 billion. Although it is not currently profitable, the stock has a forward P/E ratio of -17.65 and a beta of 0.066, indicating low volatility. The stock's 52-week range spans from $16.64 to $96.50, with a 50-day moving average of $87.18 and a 200-day moving average of $56.31.

Recent Earnings

Dianthus Therapeutics reported revenue of $1.34 million, although it experienced a revenue decline of 60.2%. The company posted a net margin of 0% and a return on equity (ROE) of -22.7%. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at Dianthus Therapeutics, Inc.

On June 1, 2026, Simrat Randhawa, EVP and Head of R&D, sold 26,530 shares at an average price of $90.62 under a Rule 10b5-1 plan. On the same day, Randhawa also bought 26,530 shares at an average price of $18.85. Additionally, insiders Simon Read, Jonathan Violin, and Paula Soteropoulos each purchased 6,090 shares on May 21, 2026.

Analysts Set New Price Targets

On May 6, 2026, Wedbush maintained its buy rating on Dianthus Therapeutics with a price target of $105. Wolfe Research initiated coverage with a buy rating and a $98 target on April 9, 2026. Meanwhile, Wells Fargo set a buy rating with a $135 target on March 19, 2026. The consensus among 12 analysts is a strong buy, with a mean target price of $127.67.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a biotechnology company based in New York, focusing on developing treatments for severe autoimmune diseases. Founded in 2019, the company is led by CEO Marino Garcia. Its key product candidates include claseprubart, a monoclonal antibody, and DNTH212, a bifunctional fusion protein. Dianthus employs 92 people and operates in the healthcare sector.

Bottom Line

RTW Investments' new stake in Dianthus Therapeutics shows growing institutional interest in the biotech firm. While the 13F filing provides a snapshot as of the reporting period, it may not reflect current holdings. With strong buy ratings from analysts and active insider trading, Dianthus Therapeutics remains a company to watch in the biotechnology sector.